President Donald Trump signed an executive order in January 2025 directing federal agencies to accelerate the review and potential approval of psychedelic-assisted therapies for military veterans suffering from treatment-resistant mental health conditions. The order, issued from the White House, instructs the Food and Drug Administration (FDA) and the Department of Veterans Affairs (VA) to prioritize research into substances like psilocybin and MDMA for conditions including post-traumatic stress disorder (PTSD) and major depressive disorder. This move marks a significant shift in federal policy toward psychedelics, which remain classified as Schedule I controlled substances under the Controlled Substances Act.
The directive comes amid growing clinical evidence suggesting psychedelic-assisted therapy can produce rapid and sustained improvements in veterans who have not responded to conventional treatments. According to a 2023 study published in Nature Medicine, MDMA-assisted therapy led to clinically significant reductions in PTSD symptoms in 67% of participants after just three sessions, with benefits lasting months beyond treatment. Similarly, research from Johns Hopkins University has shown psilocybin-assisted therapy can produce substantial and enduring decreases in depression and anxiety scores among patients with life-threatening illnesses.
Veterans advocacy groups have long pushed for expanded access to alternative therapies, citing alarming rates of suicide and untreated mental health struggles within the military community. The VA reported in its 2023 National Veteran Suicide Prevention Annual Report that an average of 17.6 veterans died by suicide each day in 2021, a rate 57.3% higher than non-veteran U.S. Adults. Proponents of the executive order argue that accelerating access to innovative treatments could help address this public health crisis.
Details of the Executive Order
The executive order, officially titled “Advancing Breakthrough Therapies for Veterans’ Mental Health,” directs the FDA to utilize its existing expedited review pathways — including Breakthrough Therapy designation and Swift Track status — for investigational recent drug applications involving psychedelics when treating PTSD or depression in veterans. It also instructs the VA to expand partnerships with academic institutions and private researchers to conduct clinical trials within the Veterans Health Administration system.
Under the order, the Secretary of Veterans Affairs is required to submit a report to the President within 180 days outlining current barriers to psychedelic research within the VA system and recommending policy changes to facilitate clinical trials. The FDA must provide a similar update on its review processes for psychedelic therapeutics targeting veteran populations within the same timeframe. These reporting requirements aim to increase transparency and accountability in the implementation of the directive.
The order does not reschedule or legalize psychedelics at the federal level, nor does it authorize their use outside of approved clinical research settings. Instead, it focuses on streamlining regulatory processes to allow for faster evaluation of safety and efficacy data. Administration officials emphasized that all research must adhere to rigorous scientific and ethical standards, including informed consent protocols and independent institutional review board oversight.
Scientific and Medical Context
Psychedelic-assisted therapy typically involves the administration of a controlled dose of a psychoactive substance in a supervised clinical setting, combined with preparatory and integrative psychotherapy sessions. Psilocybin, the active compound in certain mushrooms and MDMA (commonly known as ecstasy or Molly) are the two substances most extensively studied for mental health applications. Unlike traditional antidepressants that require daily dosing, these therapies often involve only a few sessions spaced weeks apart.
The FDA granted Breakthrough Therapy designation to MDMA-assisted psychotherapy for PTSD in 2017 and to psilocybin-assisted therapy for treatment-resistant depression in 2019. These designations are intended to expedite the development and review of drugs that show substantial improvement over existing therapies. However, final approval still requires successful completion of Phase 3 clinical trials demonstrating both efficacy and safety.
In 2023, an independent advisory committee to the FDA voted unanimously that the benefits of MDMA-assisted therapy for PTSD outweighed its risks, based on data from Phase 3 trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS). Despite this positive recommendation, the FDA has not yet issued final approval, citing the need for additional data on long-term safety and potential for misuse. Similar deliberations are ongoing for psilocybin applications.
Impact on Veterans and Stakeholder Response
The executive order has been welcomed by several veterans service organizations, including the American Legion and Veterans of Foreign Wars, which have previously passed resolutions supporting research into psychedelic therapies. Jason Kim, a former Marine Corps infantryman and advocate with the nonprofit Heroic Hearts Project, said the order “recognizes the urgency of the mental health crisis facing our veterans and opens a door that has been closed for too long.”
Medical researchers and biotech companies working in the psychedelic space have also responded positively. Shares in firms such as Compass Pathways, which is developing psilocybin therapy for treatment-resistant depression, and MindMed, which is advancing MM120 (an optimized form of LSD) for anxiety disorders, saw increased trading activity following the announcement. Analysts noted that while the order does not guarantee approval, it signals a more receptive federal environment for innovation in mental health therapeutics.
However, some public health experts have urged caution, emphasizing the need for robust scientific validation before widespread adoption. Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), acknowledged the therapeutic potential of psychedelics but stressed that “rigorous clinical trials are essential to understand both benefits and risks, particularly in vulnerable populations.” She noted that factors such as setting, dosage, and psychological support are critical determinants of outcomes.
Implementation and Next Steps
The executive order initiates a 180-day timeline for federal agencies to deliver their respective reports to the White House. The VA’s report will assess infrastructure readiness, researcher access, and ethical oversight mechanisms within the VA system. The FDA’s update will detail how We see applying expedited pathways to psychedelic investigational applications and any challenges encountered in reviewing novel trial designs.
As of May 2025, no official updates from either agency have been published in the Federal Register or on their respective websites regarding compliance with the reporting requirements. The White House has not held a public briefing on the order’s implementation since its signing. Veterans awaiting access to these therapies continue to rely on ongoing clinical trials, many of which are conducted outside the VA system and require private funding or philanthropic support.
For veterans interested in participating in authorized research studies, the VA maintains a clinical trials portal at VA Research, which lists ongoing studies across its medical centers. The FDA also provides information on eligible investigational new drug applications through its public database at Drug Development Process. Both resources are updated regularly and provide point-of-contact information for study coordinators.
The administration has indicated that future policy adjustments will depend on the outcomes of ongoing clinical trials and the agency reports mandated by the order. Until then, psychedelics remain federally illegal for recreational use, and their therapeutic application is restricted to approved research settings under strict medical supervision.
As this story develops, World Today Journal will continue to monitor official announcements from the VA, FDA, and White House for verified updates on implementation timelines, research progress, and any subsequent policy changes affecting veterans’ access to mental health innovations.
We encourage readers to share their perspectives and experiences in the comments section below. Your insights help foster informed discussion on important issues affecting our global community. If you found this article informative, please consider sharing it with others who may benefit from understanding the evolving landscape of veterans’ mental health care.